NP / PA
Hartsville, LLC
Hartsville, LLC was paid $18.42M by Medicaid between Jan 2018 and Dec 2024, across 239 billing codes. Its largest line is 36415, Collection of venous blood by venipuncture — 10% of everything it billed.
33Billing provider infoHARTSVILLE, LLC
HARTSVILLE, SC 29550
HARTSVILLE, SC 29550
33aNPI1174500458assigned 12/28/2005
33bProvider typeCertified Registered Nurse Anesthetist
28Total paid$18.42M
24GClaims682,544
24DCodes billed239
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Certified Registered Nurse Anesthetist providers in South Carolina
Rank by total paid#1 of 12
Median peer was paid$47K
This provider vs. median391×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official TRAYLOR, JOHNETTA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 98,138 | $1.88M | |
| 2019 | 96,316 | $1.95M | |
| 2020 | 81,489 | $2.09M | |
| 2021 | 93,548 | $2.78M | |
| 2022 | 108,570 | $3.48M | |
| 2023 | 105,461 | $3.75M | |
| 2024incomplete | 99,022 | $2.48M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 36415 | Collection of venous blood by venipuncture | 10% | 31,792 | 24,819 | $1.92M |
| 81025 | 10% | 10,713 | 9,924 | $1.91M | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 7.9% | 4,356 | 3,857 | $1.46M |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 7.8% | 9,177 | 8,681 | $1.44M |
| J7030 | Infusion, normal saline solution , 1000 cc | 6.9% | 8,618 | 6,996 | $1.27M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.1% | 40,530 | 36,082 | $1.12M |
| 80053 | Comprehensive metabolic panel | 6.0% | 31,547 | 25,949 | $1.10M |
| 87070 | 3.2% | 10,771 | 10,034 | $581K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.7% | 13,673 | 11,371 | $491K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.2% | 3,480 | 3,185 | $407K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.1% | 11,932 | 9,796 | $380K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.8% | 13,813 | 12,853 | $327K |
227 more codes
| 85610 | 1.6% | 6,200 | $301K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.3% | 13,193 | $242K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.1% | 4,854 | $210K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.1% | 2,803 | $203K |
| 59025 | Fetal non-stress test | 1.1% | 1,448 | $200K |
| 87280 | 1.0% | 3,459 | $190K | |
| 99284 | Emergency room visit (serious) | 1.0% | 24,761 | $188K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.0% | 1,919 | $186K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 1.0% | 5,805 | $185K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,529 | $160K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,380 | $142K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,695 | $139K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,614 | $132K |
| 73610 | <1% | 1,564 | $126K | |
| 73562 | <1% | 1,916 | $124K | |
| 81002 | <1% | 6,664 | $113K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,768 | $111K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 329 | $108K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 7,114 | $106K |
| 81001 | <1% | 16,469 | $104K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 6,909 | $104K |
| 73130 | <1% | 1,220 | $91K | |
| 86900 | <1% | 2,425 | $91K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 13,052 | $90K |
| 73630 | <1% | 1,955 | $89K | |
| 82962 | <1% | 7,766 | $88K | |
| 71045 | Radiologic examination, chest; single view | <1% | 11,559 | $86K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 994 | $84K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 553 | $81K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 401 | $79K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 8,695 | $73K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 7,388 | $72K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,084 | $69K |
| 97161 | <1% | 1,029 | $68K | |
| 73030 | <1% | 1,167 | $64K | |
| 97162 | <1% | 807 | $64K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,466 | $62K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 185 | $62K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 48,253 | $59K |
| 80306 | <1% | 3,952 | $56K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 4,200 | $52K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 12,814 | $51K |
| 84702 | <1% | 3,105 | $49K | |
| 72100 | <1% | 869 | $49K | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 665 | $47K |
| 74018 | <1% | 1,428 | $45K | |
| 88304 | <1% | 1,022 | $44K | |
| 99285 | Emergency room visit (most serious) | <1% | 11,554 | $44K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 470 | $41K |
| 93971 | <1% | 259 | $41K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 14,350 | $40K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 8,930 | $36K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 3,240 | $36K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,625 | $30K |
| 73110 | <1% | 467 | $29K | |
| 82803 | <1% | 1,134 | $28K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,128 | $27K |
| 84484 | <1% | 8,278 | $24K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 152 | $24K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,410 | $23K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,049 | $21K |
| 82565 | <1% | 1,300 | $21K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 856 | $14K |
| 42830 | <1% | 61 | $14K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 2,110 | $14K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,611 | $13K |
| 82272 | <1% | 690 | $13K | |
| 73502 | <1% | 331 | $13K | |
| 97597 | <1% | 347 | $12K | |
| 83605 | <1% | 3,253 | $12K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 185 | $12K |
| 93017 | <1% | 488 | $11K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,087 | $11K |
| 85378 | <1% | 1,705 | $11K | |
| 10060 | <1% | 100 | $11K | |
| 87210 | <1% | 1,179 | $10K | |
| 12001 | <1% | 93 | $9K | |
| 96376 | <1% | 3,199 | $9K | |
| 71250 | <1% | 68 | $9K | |
| 76536 | <1% | 80 | $9K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,409 | $8K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 15 | $8K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 176 | $8K |
| 72040 | <1% | 88 | $8K | |
| 95782 | <1% | 12 | $7K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 416 | $7K |
| G0378 | Hospital observation service, per hour | <1% | 3,179 | $6K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,133 | $6K |
| 74022 | <1% | 242 | $5K | |
| 94664 | <1% | 1,389 | $5K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,818 | $5K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 810 | $5K |
| 95811 | <1% | 12 | $5K | |
| 97032 | <1% | 71 | $4K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 43 | $4K |
| 87186 | <1% | 4,904 | $4K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 418 | $4K |
| 87077 | <1% | 2,224 | $4K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,712 | $4K |
| 36600 | <1% | 1,166 | $4K | |
| 83690 | <1% | 5,951 | $4K | |
| 90715 | <1% | 200 | $4K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,139 | $3K |
| 76642 | <1% | 82 | $3K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,094 | $3K |
| 76830 | Ultrasound, transvaginal | <1% | 14 | $3K |
| 84145 | <1% | 453 | $3K | |
| 86850 | <1% | 1,678 | $3K | |
| 84112 | <1% | 24 | $3K | |
| 80320 | <1% | 1,801 | $3K | |
| 30140 | <1% | 125 | $3K | |
| 59050 | <1% | 328 | $3K | |
| J3490 | Unclassified drugs | <1% | 3,518 | $3K |
| 87088 | <1% | 4,016 | $3K | |
| 94060 | <1% | 65 | $3K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 146 | $3K |
| 72131 | <1% | 32 | $2K | |
| 73080 | <1% | 63 | $2K | |
| 73590 | <1% | 71 | $2K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 889 | $2K |
| 82150 | <1% | 993 | $2K | |
| 84520 | <1% | 1,116 | $2K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 394 | $2K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,371 | $2K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 18 | $2K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 46 | $2K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,435 | $2K |
| 84439 | <1% | 3,708 | $2K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 508 | $2K |
| 83735 | <1% | 9,128 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 8,288 | $2K |
| 76770 | <1% | 30 | $1K | |
| 99001 | <1% | 1,395 | $1K | |
| 29580 | <1% | 68 | $1K | |
| 80076 | <1% | 312 | $1K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 221 | $1K |
| 97116 | <1% | 118 | $1K | |
| 83880 | <1% | 3,272 | $1K | |
| 73552 | <1% | 24 | $1K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 786 | $984.01 |
| 86141 | <1% | 1,174 | $960.72 | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 41 | $958.76 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,556 | $958.03 |
| 76801 | <1% | 25 | $868.38 | |
| 73140 | <1% | 17 | $863.27 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,342 | $654.23 |
| 80177 | <1% | 29 | $624.56 | |
| 85651 | <1% | 1,646 | $598.64 | |
| 51702 | <1% | 15 | $582.58 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 702 | $489.34 |
| 86592 | <1% | 264 | $474.59 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,081 | $470.69 |
| 10061 | <1% | 17 | $405.74 | |
| 87045 | <1% | 16 | $400.40 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 14 | $384.60 |
| 82607 | <1% | 2,514 | $384.28 | |
| 70486 | <1% | 16 | $367.42 | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 82 | $305.46 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,639 | $287.74 |
| 80061 | Lipid panel | <1% | 4,216 | $287.59 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,298 | $277.74 |
| 87040 | <1% | 3,111 | $274.64 | |
| 85014 | <1% | 212 | $257.61 | |
| 85730 | <1% | 4,710 | $252.00 | |
| 82728 | <1% | 741 | $223.19 | |
| 97166 | <1% | 14 | $218.29 | |
| 82550 | <1% | 162 | $202.72 | |
| 83540 | <1% | 1,026 | $149.65 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 325 | $135.76 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,362 | $116.83 |
| 82950 | <1% | 1,441 | $97.37 | |
| 87205 | <1% | 1,325 | $74.49 | |
| 82570 | <1% | 230 | $69.68 | |
| 87075 | <1% | 83 | $65.14 | |
| 84156 | <1% | 163 | $62.86 | |
| 84153 | <1% | 433 | $59.95 | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 815 | $48.68 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,768 | $29.54 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 829 | $27.90 |
| 86901 | 0% | 2,424 | $0.00 | |
| J2704 | Injection, propofol, 10 mg | 0% | 3,516 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 68 | $0.00 |
| G0379 | Direct admission of patient for hospital observation care | 0% | 77 | $0.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 404 | $0.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 770 | $0.00 |
| 82746 | 0% | 336 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 382 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 53 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 147 | $0.00 |
| C1769 | Guide wire | 0% | 13 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 281 | $0.00 |
| 85018 | 0% | 199 | $0.00 | |
| 94762 | 0% | 485 | $0.00 | |
| 83550 | 0% | 70 | $0.00 | |
| 88307 | 0% | 12 | $0.00 | |
| 87046 | 0% | 16 | $0.00 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 14 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 19 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 50 | $0.00 |
| 84134 | 0% | 30 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 13 | $0.00 |
| J0561 | Injection, penicillin g benzathine, 100,000 units | 0% | 17 | $0.00 |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | 0% | 33 | $0.00 |
| 84100 | 0% | 330 | $0.00 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 1,090 | $0.00 |
| 94799 | 0% | 206 | $0.00 | |
| 84550 | 0% | 80 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 95 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 231 | $0.00 |
| 76000 | 0% | 37 | $0.00 | |
| 94726 | 0% | 50 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 299 | $0.00 |
| 82247 | 0% | 44 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 35 | $0.00 |
| 94150 | 0% | 17 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 94 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 14 | $0.00 |
| 94729 | 0% | 47 | $0.00 | |
| 85044 | 0% | 30 | $0.00 | |
| 82248 | 0% | 35 | $0.00 | |
| 83525 | 0% | 25 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 12 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 12 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 36 | $0.00 |
| 84466 | 0% | 22 | $0.00 | |
| 83020 | 0% | 12 | $0.00 | |
| 86038 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTRAYLOR, JOHNETTA (DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Logan General Hospital LLC | Logan, WV | $43.43M |
| Phc-Cleveland LLC | Cleveland, MS | $23.43M |
| Logan Memorial Hospital LLC | Russellville, KY | $14.29M |
| Southwestern Medical Center, LLC | Lawton, OK | $9.40M |
| Palestine Principal Healthcare Limited Partnership | Palestine, TX | $6.80M |
| Watertown Medical Center LLC | Watertown, WI | $6.31M |
| Amg - Livingston, LLC | Livingston, TN | $5.52M |
| Logan General Hospital LLC | Logan, WV | $4.91M |
| ST. Joseph Hospital LLC | Lewiston, ID | $4.67M |
| Riverton Memorial Hospital LLC | Riverton, WY | $4.65M |
| Livingston Regional Hospital LLC | Livingston, TN | $4.33M |
| Hartsville Medical Group LLC | Hartsville, SC | $4.16M |
| Mexia Principal Healthcare Limited Partnership | Mexia, TX | $2.19M |
| Palestine Principal Healthcare Limited Partnership | Palestine, TX | $1.27M |
| Texas Specialty Physicians | Palestine, TX | $1.26M |
| ST Joseph Hospital LLC | Lewiston, ID | $1.10M |
| Watertown Physician Practices LLC | Watertown, WI | $244K |
| Watertown Physician Practices LLC | Watertown, WI | $175K |
| Amg-Livingston LLC | Livingston, TN | $165K |
| Watertown Physician Practices LLC | Watertown, WI | $149K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.